Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Breast 1

Conditions

Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Ovarian Neoplasms 1Breast Neoplasms 1

Interventions

Specimen Handling 199Magnetic Resonance Spectroscopy 154Biopsy 120pembrolizumab 89Carboplatin 88Cisplatin 78Cyclophosphamide 75Nivolumab 73Paclitaxel 69Radiotherapy 50Gemcitabine 48durvalumab 43Bevacizumab 42Doxorubicin 39Fluorouracil 37Dexamethasone 37venetoclax 34Capecitabine 34olaparib 32Etoposide 32Rituximab 31Radiation 31Oxaliplatin 31Lenalidomide 31atezolizumab 29Taxes 29Pemetrexed 29Injections 29Docetaxel 29fludarabine 28

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Bupropion × 30 days × Clear all
NCT03180294 2026-05-19

Bupropion Hydrochloride in Improving Sexual Desire in Women With Breast or Gynecologic Cancer

NRG Oncology

Phase 2 Completed
230 enrolled 24 charts
BreastGynecologic

Breast Neoplasms, Uterine Cervical Neoplasms, Ovarian Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡